Topic: Outsourcing and Offshoring Trends in Pharmaceuticals – Preview Deck

Global Sourcing
Report: October 2011
Background, objective, and scope of the research

Description

- This report analyzes key outsourcing and offshoring trends in the pharmaceuticals (pharma) vertical across multiple dimensions and examines how leading pharma majors maximized value from global sourcing
- We have considered pharma companies such as GlaxoSmithKline, Pfizer, J&J, Novartis, and Merck to be representative of the buyers in this industry

Background

- Trace the evolution and adoption of global sourcing of services in the pharma industry
- Develop perspectives on potential themes and opportunities that may influence the outsourcing and offshoring landscape in the future
- Offer insights on service provider landscape for pharmaceutical companies

Objective

- **Outsourcing contracts**: All publicly announced third-party BPO and ITO deals in the pharmaceuticals vertical, signed during January 2006 to June 2011. In addition, the report includes analyses based on multi-/single-process outsourcing deals from Everest Group's proprietary account intelligence databases
- **Captives landscape**: Analyses on captive landscape of leading pharma companies
- **Services scope**: BPO (across FAO, HRO, PO, pharma-specific services), ITO (across Infrastructure Outsourcing – IO, and Applications Outsourcing – AO), R&D, supply chain, and sales and marketing
- **Geographic focus**: Global, including Americas (North America and Latin America), Western Europe, Central and Eastern Europe (CEE), Middle East, and Africa (MEA), and Asia Pacific (APAC)
- **Service provider landscape**: Key service providers that signed deals, which are in the public domain, with buyers in the pharmaceuticals vertical
# Table of contents (page 1 of 2)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive summary</td>
<td>6</td>
</tr>
<tr>
<td>Section I: Background</td>
<td>10</td>
</tr>
<tr>
<td>– Summary</td>
<td>11</td>
</tr>
<tr>
<td>– Pharmaceuticals industry landscape and trends</td>
<td>12</td>
</tr>
<tr>
<td>– Factors promoting and inhibiting growth of global sourcing by pharma companies</td>
<td>16</td>
</tr>
<tr>
<td>Section II: Outsourcing market trends</td>
<td>17</td>
</tr>
<tr>
<td>– Summary</td>
<td>18</td>
</tr>
<tr>
<td>– Transaction analysis by number of deals and deal size</td>
<td>19</td>
</tr>
<tr>
<td>– Scope of services</td>
<td>23</td>
</tr>
<tr>
<td>– Deal activity by signing region</td>
<td>25</td>
</tr>
<tr>
<td>– Deals nearing end-of-term</td>
<td>27</td>
</tr>
<tr>
<td>Section III: Trends across buyer adoption and sourcing models</td>
<td>28</td>
</tr>
<tr>
<td>– Summary</td>
<td>29</td>
</tr>
<tr>
<td>– Analysis of total and outsourced spend</td>
<td>31</td>
</tr>
<tr>
<td>– Trends in adoption of outsourcing and offshoring across the pharma value chain</td>
<td>32</td>
</tr>
<tr>
<td>– Sourcing models leveraged by pharmaceutical majors</td>
<td>35</td>
</tr>
<tr>
<td>– Case study: Pharma major</td>
<td>37</td>
</tr>
<tr>
<td>– Captives of pharmaceutical firms: Locations and scope of services</td>
<td>38</td>
</tr>
</tbody>
</table>
Table of contents (page 2 of 2)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section IV: Service provider landscape</strong></td>
<td>40</td>
</tr>
<tr>
<td>– Summary</td>
<td>41</td>
</tr>
<tr>
<td>– Overall service provider landscape</td>
<td>42</td>
</tr>
<tr>
<td>– Trends in number of deals by service provider category</td>
<td>43</td>
</tr>
<tr>
<td>– Service offerings and functional capability assessment</td>
<td>45</td>
</tr>
<tr>
<td>– Perspectives on service provider capability expansion in pharma-specific services</td>
<td>48</td>
</tr>
<tr>
<td><strong>Section V: Future trends to monitor</strong></td>
<td>52</td>
</tr>
<tr>
<td>– Key future trends to watch</td>
<td>53</td>
</tr>
<tr>
<td>– Opportunities for higher outsourcing adoption</td>
<td>54</td>
</tr>
<tr>
<td>– Evolution of the pharmaceuticals value chain</td>
<td>55</td>
</tr>
<tr>
<td>– Impact of U.S. healthcare reform</td>
<td>56</td>
</tr>
<tr>
<td>– Opportunities and imperatives for service providers</td>
<td>57</td>
</tr>
<tr>
<td><strong>Glossary of key terms</strong></td>
<td>58</td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>60</td>
</tr>
</tbody>
</table>
This research report provides an in-depth analysis of the outsourcing market trends in the global pharmaceuticals vertical.

Deal signings in the pharmaceuticals vertical increased at a faster pace than other verticals in 2010.

The ACV has been steadily increasing since 2008, while the average deal duration has been reducing.

XX dominated activity within ITO and YY dominated activity within BPO.

The pharmaceuticals vertical is an active outsourcer of IT services, with most companies leveraging third parties for development, maintenance, and systems integration needs. In the past five years, buyer adoption of third-party infrastructure services increased. On the BPO side, a majority of the deals were in the XX, YY, and ZZ services.

XX dominated deal signings over the past three years.

Pharmaceutical companies account for xx% of all deals in healthcare.
The pharma vertical witnessed a significant increase in transactions in 2010

The need for cost containment and the focus on increasing efficiencies drove adoption of outsourcing in the pharmaceutical space in 2010. The spike in transactions was also due to pent-up demand from the previous two years. This led to a larger number of transactions being signed in 2010.

Some notable transactions signed in 2010 include:

- Buyer 1’s US$XX billion R&D deal signed with YY in 2010
- Buyer 2’s US$XX million IT-BPO deal with YY
- Buyer 3’s IT deal with XX (deal value not publicly disclosed)

1H 2011 has been somewhat slower compared to 1H 2010 (which witnessed ~XX transactions) with no significant deal signed by any pharma major.

Source: Everest Group

---

1 Does not include deals signed in 2011
XX dominated deal signings over the past three years

Historically, the U.S.-based pharmaceuticals majors drove the demand for outsourced services. However, the past three years witnessed several XX pharmaceuticals adopt third-party outsourcing services. Examples of key contracts include those signed between AA and BB, CC and DD, and EE and FF.

1 Buyer geography unknown for XX deals out of the total YY deals signed in the pharmaceutical vertical during 2006-1H 2011

Source: Everest Group
The report analyzes trends in buyer adoption of outsourcing and sourcing models used

These are the three primary dimensions of buyer adoption of global sourcing:

1. **What are buyers sourcing**
   - Functions
   - Processes

2. **How are buyers sourcing**
   - Sourcing models (captive & third-party)
   - Sourcing mix

3. **Where are buyers sourcing from**
   - Locations
   - Global network

Buyers leverage hybrid sourcing models, although the extent of XX varies.

Knowledge services are also emerging as a high-potential area for offshore support:

<table>
<thead>
<tr>
<th>Functions</th>
<th>Drug discovery/research</th>
<th>Development</th>
<th>Manufacturing operations</th>
<th>Marketing and sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Processes</td>
<td>AA</td>
<td>CC</td>
<td>RR</td>
<td>SS</td>
</tr>
<tr>
<td>Data sourcing and provisioning</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data management</td>
<td>BB</td>
<td>KK</td>
<td>RR</td>
<td>SS</td>
</tr>
<tr>
<td>Market and business research</td>
<td>GG</td>
<td>HH</td>
<td>MM</td>
<td>TT</td>
</tr>
<tr>
<td>Reporting/BI</td>
<td>FF</td>
<td>LL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analytics and design</td>
<td>GG</td>
<td>HH</td>
<td>MM</td>
<td>TT</td>
</tr>
<tr>
<td>Intellectual property management</td>
<td>JJ</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Most offshore captives are located in XX; captives are leveraged for different services in Asia and CEE.

Adoption of global sourcing by pharma majors across functions:

<table>
<thead>
<tr>
<th>Buyer</th>
<th>XX</th>
<th>XX</th>
<th>XX</th>
<th>XX</th>
<th>XX</th>
<th>XX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buyer 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buyer 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buyer 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buyer 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buyer 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Most processes sourced through a hybrid model (captive and third-party); only XX, XX, and (to some extent) XX are sourced through either model.
Outsourced spend is ~XX percent of total industry expenses; XX services dominate outsourced spend

Split of services spend

<table>
<thead>
<tr>
<th>Functions</th>
<th>Drug discovery/research</th>
<th>Development</th>
<th>Manufacturing operations</th>
<th>Marketing and sales</th>
<th>Supply chain &amp; distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total industry spend</td>
<td>XX-YY</td>
<td>XX-YY</td>
<td>XX-YY</td>
<td>XX-YY</td>
<td>XX-YY</td>
</tr>
</tbody>
</table>

Total vs. outsourced spend
US$ billion, 2011

Break-up of total outsourced spend
Percentage and US$ billion, 2011

1 Excludes one-time spend, includes spend on materials
Source: Everest Group analysis

Copyright © 2011, Everest Global, Inc.
EGR-2011-2-PD-0600
Big pharma companies display various approaches of sourcing work; all of them use a XX model

Comparison of various sourcing approaches

<table>
<thead>
<tr>
<th>Buyer</th>
<th>Extent of outsourcing</th>
<th>Highlights of sourcing model</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Captive/in-house</strong></td>
<td><strong>Third party</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Buyer 1 | ![Captive/in-house](image1) ![Third party](image2) | ● Captives provide primarily XX and YY  
● XX, YY, and ZZ are sourced from third parties |
| Buyer 2 | ![Captive/in-house](image3) ![Third party](image4) | ● Captives provide primarily XX and YY  
● XX, YY, and ZZ are sourced from third parties |
| Buyer 3 | ![Captive/in-house](image5) ![Third party](image6) | ● XX and YY are outsourced to third parties  
● Shared services centers are leveraged to deliver other services |
| Buyer 4 | ![Captive/in-house](image7) ![Third party](image8) | ● Captives provide primarily XX and YY  
● XX, YY, and ZZ are sourced from third parties |
| Buyer 5 | ![Captive/in-house](image9) ![Third party](image10) | ● Captives provide primarily XX and YY  
● XX, YY, and ZZ are sourced from third parties  
● Some parts of XX and YY, and a significant part of ZZ is outsourced to third-party providers |

- Buyers display a mix of approaches; models differ even at the function level in some cases
- Overall, the market is skewed towards XX; a mix of YY and ZZ is leveraged

Source: Everest Group analysis
The report also provides an overview of the service provider landscape and their capabilities.
**XX account for the largest share in terms of number of transactions**

**Distribution by service provider category**

2006-1H 2011; Number of deals

- Global service providers such as AA, BB, CC, DD account for the largest share in the pharmaceuticals space in terms of number of transactions over the past five years.

- Indian-heritage service providers such as AA, BB, and CC account for XX percent of the market based on number of transactions. A large number of the Indian-heritage service providers increased focus on the pharmaceuticals space over the last decade and firmed up their capabilities through organic, as well as, inorganic means.

- Pharma-specific service providers such as pharma sales and marketing specialists like AA, and clinical data management specialists such as BB account for XX percent of all deals. Pharma sales and marketing is one of the most outsourced functions in the pharma space.

Source: Everest Group analysis
Service providers are extending capabilities to move up the pharma value chain

- Several service providers have taken the inorganic route to build capabilities across the value chain – especially in XX, YY, and ZZ
- Examples include XX’s acquisition of YY in ZZ and XX’s acquisition of YY, in ZZ

- Mergers and acquisitions
  - Capability expansion through establishment of centers of excellence, new service offerings etc. further show service providers’ increasing focus on the pharmaceuticals space
  - Examples include XX’s planned investments to grow its pharma capabilities in YY, AA’s planned BB in CC

- Alliances also contributed to capability expansion
  - Examples include AA’s alliance with BB, CC’s alliance with DD, EE’s alliance with FF

Source: Everest Group analysis
The report discusses the key future trends to watch

**Pharma industry is battling rising R&D expenditure with declining new drug approvals**

- **U.S. Pharma R&D Expenditure**
  - US$ billion
  - "96 "98 "00 "02 "04 "06 "08 "10
  - Data: 1996-2010

- **New drug approvals**
  - Number
  - "96 "98 "00 "02 "04 "06 "08 "10

**XX markets offer growth opportunity, but also present unique challenges**

- **Pharma industry revenues**
  - 2010-2015; US$ billion

**A Opportunities for additional outsourcing continue to exist**

- **Functions**
  - AA BB CC DD EE FF GG HH

- **Total current spend**
  - US$ billion, 2011

- **Current versus potential outsourcing spend**
  - US$XX-YY billion

**B The pharma value chain model is moving towards a “value hub” model**

- **Conventional value chain**
  - Drug discovery/research
  - Development
  - Manufacturing operations
  - Supply chain & distribution
  - Marketing and sales

- **“Value hub”**
  - Partnering with multiple entities across the value chain helps pharma companies access the best-in-breed capabilities in respective components of the value chain and achieve growth objectives in a cost-effective manner.
  - Efficient functioning of the “value hub” model will require tools and processes to enable XX, YY, and ZZ.
  - Involvement of multiple partners in the process necessitates strong XX and YY.
Additional research references

The following documents are recommended for additional insight on the topic covered in this Research Report. The recommended documents either provide additional details on the topic or complementary content that may be of interest.

1. **Outsourcing and Service Provider Landscape in Germany** (ERI-2011-2-R-0531); 2011. This report summarizes the key trends and developments for Q2 2010 in the global offshoring and outsourcing market.

2. **IT Application Outsourcing in Insurance – Trends and Future Outlook** (EGR-2011-11-R-0594); 2011. This report analyzes the trends and next generation imperatives for suppliers along some of the key components of global delivery – location portfolio, operating model, and talent management. The report presents the global delivery trends with pertinent examples, data analysis and observations, and draws important implications for suppliers as well as buyers of outsourcing services.

3. **IT Applications in Banking – Trends and Future Outlook** (ERI-2011-11-R-0566); 2011. Everest conducted a market survey to understand the current location footprint, expansion plans, and perceptions of risk in offshore locations. This whitepaper provides an overview of how buyers are thinking about their expansion plans, specifically with respect to scale and locations. The document also explores typical location risk perceptions of buyer organizations.

For more information on this and other research published by the Everest Group, please contact us:

**Amneet Singh**, Vice President – Global Sourcing: amneet.singh@everestgrp.com
**H. Karthik**, Vice President – Global Sourcing: hkarthik@everestgrp.com
**Anurag Srivastava**, Senior Research Analyst: anurag.srivastava@everestgrp.com
**Saumya Chaturvedi**, Research Analyst: saumya.chaturvedi@everestgrp.com

Everest Group
Two Galleria Tower
13455 Noel Road, Suite 2100
Dallas, TX 75240

Phone: +1-214-451-3110
E-mail: info@everestgrp.com
About Everest Group

Everest Group is an advisor to business leaders on the next generation of global services with a worldwide reputation for helping Global 1000 firms dramatically improve their performance by optimizing their back- and middle-office business services. With a fact-based approach driving outcomes, Everest Group counsels organizations with complex challenges related to the use and delivery of global services in their pursuits to balance short-term needs with long-term goals. Through its practical consulting, original research and industry resource services, Everest Group helps clients maximize value from delivery strategies, talent and sourcing models, technologies and management approaches. Established in 1991, Everest Group serves users of global services, providers of services, country organizations and private equity firms, in six continents across all industry categories. For more information, please visit www.everestgrp.com and research.everestgrp.com.
Everest Group leads clients from insight to action

Contact us for more information about our consulting, research, and industry resources.

Dallas (Corporate Headquarters)
info@everestgrp.com
+1-214-451-3000
+1-214-451-3110

Canada
canada@everestgrp.com
+1-416-865-2033

New York
info@everestgrp.com
+1-646-805-4000

United Kingdom
unitedkingdom@everestgrp.com
+ 44-207-887-1483

India/Middle East
india@everestgrp.com
+91-124-496-1000
+91-124-496-1100

Netherlands & Continental Europe
benelux@everestgrp.com
+31-20-301-2138

www.everestgrp.com  |  research.everestgrp.com  |  www.sherpasinblueshirts.com